HER2-positive Breast CancerDEFINITIVENCT06446882
Diagnostic HER2DX-guided Treatment for Patients wIth Early-stage HER2-positive Breast Cancer
A study testing Personalized treatment according to molecular diagnosis with HER2DX and Treatment by physician´s choice, blinded to the diagnostic HER2DX test results in people with HER2-positive Breast Cancer and Early-stage Breast Cancer, run by Fundacio Clinic Barcelona at 29 sites in 5 countries.
Trial summary
The primary goal of the DEFINITIVE trial is to demonstrate the effectiveness of the HER2DX diagnostic assay in enhancing the management of patients with early-stage HER2- positive breast cancer. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- HER2-positive Breast Cancer, Early-stage Breast Cancer
- What is being tested?
- Personalized treatment according to molecular diagnosis with HER2DX and Treatment by physician´s choice, blinded to the diagnostic HER2DX test results
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 304 participants
- Where
- 29 sitesin 5 countries
- Study dates
- 11 Oct 2024to Nov 2028
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Signed informed consent must be obtained prior to any trial-specific procedure. Note: Candidate patients in France must be affiliated to a Social Security System (or equivalent).
- Male/female patients who are at least 18 years of age on the day of signing informed consent.
- Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
- Eligible for any of the following drugs: taxane, carboplatin, trastuzumab, pertuzumab and T-DM1 therapy.
- Histologically confirmed non-metastatic primary invasive adenocarcinoma of the breast untreated and recently diagnosed.
- Stage at presentation: cT1 cN1-2 or cT2-3 cN0-2 as determined by AJCC staging system, 8th edition (specifically in accordance with Anatomic Stage group rules).
Show all 27Show fewer
- Note: Axillary lymph node status must be assessed by fine needle biopsy or core biopsy. This procedure at screening will be omitted if there is no suspicion for positive axillary lymph node(s) radiographically or if a pathological report of suspicious lymph nodes of the results of a fine needle biopsy or core biopsy is available prior to the screening period.
- Absence of distant metastasis (i.e., cM0).
- Patients with multifocal tumors (more than one mass confined to the same quadrant as primary tumor) are eligible provided at least one focus is sampled and locally confirmed as HER2-positive.
- Patients with multicentric tumors (multiple tumors involving more than one quadrant) are eligible provided all discrete lesions are sampled and locally confirmed as HER2-positive.
- Note: In patients with multifocal or multicentric breast cancer, the largest lesion should be measured to determine T stage and to performe the HER2DX test.
- HER2 positivity defined as either of the following: IHC 3+ or HER2 2+/ ISH positive as per most recent ASCO- CAP guideline according to the local laboratory as determined on the most recently analyzed tissue sample.
- ER/PR status determined local based on pretreatment breast biopsy material according to the most recent ASCO/CAP guidelines.
- Candidates for neoadjuvant treatment.
- Patient agreement to undergo appropriate surgical management, including axillary lymph node surgery and partial or total mastectomy, after completion of neoadjuvant treatment
- Baseline left ventricular ejection fraction (LVEF) ≥ 50% measured by echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scans.
- Availability of pre-treatment tumor tissue sample of FFPE tumor block from primary tumor in the breast for diagnostic HER2DX test. The tumor tissue should be of good quality based on total and viable tumor content and must be evaluated centrally for quality prior to enrollment. Archival tumor tissue or ex professo biopsy are acceptable.
- Adequate hematologic and end-organ function.
- For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods, and agreement to refrain from donating eggs, as defined below:
- Women must remain abstinent or use contraceptive methods with a failure rate of < 1% per year during the treatment period, 6 months after the final dose of doxorubicin, 12 months after the final dose of cyclophosphamide, 6 months after the final dose of paclitaxel, and 7 months after the final dose of trastuzumab, pertuzumab, or T-DM1, whichever occurs last. Women must refrain from donating eggs during this same period.
- A woman is of childbearing potential if she is postmenarcheal, has not reached a postmenopausal state (> 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus). The definition of childbearing potential may be adapted for alignment with local guidelines or requirements.
- Examples of contraceptive methods with a failure rate of < 1% per year include bilateral tubal ligation, male sterilization, copper intrauterine devices, hormonal contraceptives that inhibit ovulation, and hormone-releasing intrauterine devices in women with hormone receptor-negative tumors only; the use of hormonal contraceptives and hormone releasing intrauterine devices are prohibited in women with hormone receptor-positive tumors.
- The reliability of sexual abstinence should be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.
- For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as defined below:
- With a female partner of childbearing potential who is not pregnant, men who are not surgically sterile must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of < 1% per year during the treatment period and for 6 months after the final dose of doxorubicin and/or cyclophosphamide, 6 months after the final dose of paclitaxel, and 7 months after the final dose of trastuzumab, pertuzumab, or T-DM1, whichever occurs last. Men must refrain from donating sperm during this same period. Male patients are encouraged to seek advice regarding cryoconservation of sperm prior to commencing study treatment because of the possibility of infertility with CT.
- With a pregnant female partner, men must remain abstinent or use a condom during the treatment period and for 6 months after the final dose of doxorubicin and/or cyclophosphamide, 6 months after the final dose of paclitaxel, and 7 months after the final dose of trastuzumab, pertuzumab, or T-DM1, whichever occurs last to avoid exposing the embryo.
- The reliability of sexual abstinence should be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.
Who cannot join
- Stage IV (metastatic) breast cancer.
- Known hypersensitivity to any of the excipients of trastuzumab, pertuzumab, carboplatin, T-DM1, docetaxel or paclitaxel.
- Patients with synchronous bilateral invasive breast cancer.
- Prior systemic therapy for treatment of breast cancer.
- Ulcerating or inflammatory breast cancer.
- Undergone incisional and/or excisional biopsy of primary tumor and/or axillary lymph nodes.
Show all 24Show fewer
- Sentinel lymph node procedure or axillary lymph node dissection prior to initiation of neoadjuvant therapy.
- Patients with a history of previous breast cancer are excluded. Patients with a history of any other cancers (except non-melanoma skin cancer or carcinoma in situ of the cervix), unless in complete remission with no therapy for a minimum of 3 years are excluded. For patients with a history of other non-breast cancerscancerscancers within 3 years and considered of low risk of recurrence per investigator's judgment (for example, papillary thyroid cancer treated with surgery), eligibility is to be discussed with the Sponsor.
- Cardiopulmonary dysfunction as defined by any of the following prior to randomization:
- History of congestive heart failure of any classification.
- Angina pectoris requiring anti-anginal medication, serious cardiac arrhythmia not controlled by adequate medication, severe conduction abnormality, or clinically significant valvular disease.
- High-risk uncontrolled arrhythmias (i.e., atrial tachycardia with a heart rate > 100/min at rest, significant ventricular arrhythmia [ventricular tachycardia], or higher-grade atrioventricular [AV]-block [second degree AV-block Type 2 [Mobitz 2] or third-degree AV-block]).
- Significant symptoms (Grade > 1) relating to left ventricular dysfunction, cardiac arrhythmia, or cardiac ischemia.
- Myocardial infarction within 12 months prior to randomization.
- Evidence of transmural infarction on ECG.
- Requirement for oxygen therapy.
- Dyspnea at rest.
- Major surgical procedure, other than for diagnosis, within 4 weeks prior to initiation of study treatment or anticipation of need for a major surgical procedure during the Study.
- Severe infection within 4 weeks prior to initiation of Study treatment, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia.
- History of significant co-morbidities that, in the judgment of the investigator, may interfere with the conduction of the Study, the evaluation of response, or with consent procedure.
- Pregnancy or breastfeeding, or intention of becoming pregnant during Study treatment or within 6 months after the final dose of paclitaxel, or 7 months after the final dose of trastuzumab, pertuzumab, or T-DM1, whichever occurs last.
- Note: Women of childbearing potential must have a negative serum pregnancy test result within 7 days prior to initiation of Study treatment.
- Persons deprived of their liberty or under protective custody or guardianship.
- Patients unwilling or unable to comply with the medical follow-up required by the trial because of geographic, familial, social, or psychological reasons.
Trial locations and contacts
29 sites in 5 countries. Contact the study team or a site near you to ask about taking part.
Olga Martínez, MD contact
29 sites in 5 countries
Spain10 sites, 10 recruiting
- Recruiting
Instituto Catalán de Oncología (ICO) - Badalona
Badalona
Anna Pous, MD, definitive@gruposolti.org
- Recruiting
Hospital Universitario de Basurto
Bilbao, Vizcaya, 48013
Elena Galve, MD, definitive@gruposolti.org
- Recruiting
Hospital Universitario Clínico San Cecilio
Granada, Granada, 18007
Isabel Blancas, MD, definitive@gruposolti.org
- Recruiting
Instituto Catalán de Oncología (ICO) - Hospitalet
L'Hospitalet de Llobregat, Barcelona, 08908
Sonia Pernas, MD, definitive@gruposolti.org
- Recruiting
Complejo Asistencial Universitario de León
León, León, 24008
Mariana López Flores, MD, definitive@gruposolti.org
- Recruiting
Hospital Universitario Ramón y Cajal
Madrid, Madrid, 28034
Elena López Miranda, MD, definitive@gruposolti.org
- Recruiting
Hospital Clínico Universitario Virgen de Arrixaca
Murcia, Murcia, 30120
Pilar Sánchez Henarejos, MD, definitive@gruposolti.org
- Recruiting
Hospital Universitario Sant Joan de Reus
Reus, Tarragona, 42301
Kepa Amilano, MD, definitive@gruposolti.org
- Recruiting
Hospital Universitario de Salamanca
Salamanca
César Rodríguez, MD, definitive@gruposolti.org
- Recruiting
Hospital Clínico Universitario de Santiago
Santiago de Compostela, La Coruña, 15706
Teresa Curiel, MD, definitive@gruposolti.org
Austria9 sites, 9 recruiting
- Recruiting
MUG-Univ.-Klinik für Frauenheilkunde und Geburtshilfe, Klinische Abteilung für Gynäkologie
Graz
Vassiliki Kolovetsiou-Kreiner, MD, definitive@gruposolti.org
- Recruiting
Lkh Hochsteiermark-Leoben
Leoben
Thamer Sliwa, definitive@gruposolti.org
- Recruiting
Ordensklinikum Linz, Barmherzige Schwestern, Bhs
Linz
Renate Pusch, definitive@gruposolti.org
- Recruiting
Uniklinikum Salzburg
Salzburg
Richard Greil, definitive@gruposolti.org
- Recruiting
Universitätsklinikum St.Pölten
Sankt Pölten
Martin Wiesholzer, MD, definitive@gruposolti.org
- Recruiting
Hanusch Krankenhaus
Vienna
Jan Miechowiecki, MD, definitive@gruposolti.org
- Recruiting
Klinik Hietzing, Gynäkologische Abteilung - Karl Landsteiner Institut für gyn. Onkologie
Vienna
Christian Peters-Engl, MD, definitive@gruposolti.org
- Recruiting
Medizinische Universität Wien, Allg. Gynäkologie und Gyn. Onkologie
Vienna
George Pfeiler, MD, definitive@gruposolti.org
- Recruiting
Klinikum Wels-Grieskirchner
Wels
Sonja Heibl, definitive@gruposolti.org
France7 sites, 7 recruiting
- Recruiting
Sainte-Catherine - Institut du Cancer Avignon-Provence
Avignon
Julien Grenier, MD, definitive@gruposolti.org
- Recruiting
Polyclinique Bordeaux Nord
Bordeaux
Nadine Dohollou, MD, definitive@gruposolti.org
- Recruiting
Centre León Bérard
Léon
Benoite Mery, MD, definitive@gruposolti.org
- Recruiting
Institut Paoli Calmettes
Marseille
Alexandre Tassin de Nonneville, MD, definitive@gruposolti.org
- Recruiting
Institut de Cancérologie de Lorraine
Nancy
Albane Lhuillier, MD, definitive@gruposolti.org
- Recruiting
Gustave Roussy
Paris
Alessandro Viansone, MD, definitive@gruposolti.org
- Recruiting
Oncopole Claudius Regaud, IUCT-Oncopole
Toulouse
Florence Dalec, MD, definitive@gruposolti.org
Italy2 sites, 2 recruiting
- Recruiting
Istituto Europeo di Oncologia
Milan
Giuseppe Curigliano, MD, definitive@gruposolti.org
- Recruiting
Institute Oncology Veneto
Padova
Valentina Guarnieri, MD, definitive@gruposolti.org
Israel1 site, 1 recruiting
- Recruiting
Sheba Medical Center
Ramat Gan
Einav Nili, definitive@gruposolti.org
About this study
Official title: Diagnostic HER2DX-guided Treatment for patIents wIth Early-stage HER2-positive Breast Cancer
The primary goal of the DEFINITIVE trial is to demonstrate the effectiveness of the HER2DX diagnostic assay in enhancing the management of patients with early-stage HER2- positive breast cancer.
Patients randomized to arm A will receive adjuvant treatment by physician´s choice, blinded to the diagnostic HER2DX test results. Patients randomized to Arm B will receive personalized treatment according to HER2DX results.
Read the detailed description
This is an international, multicenter, prospective, randomized, two-arm, open-label, phase III study to evaluate the HRQoL, safety, efficacy, and economical costs of using HER2DX in patients with stage II to IIIA HER2-positive breast cancer, suitable for neoadjuvant therapy.
A dual primary endpoint with an according multiple testing procedure is defined in this study. First, the study will evaluate superiority in quality of life using i) the GHS scale from the EORTC QLQ-C30 questionnaire version 3.0 and ii) the score from the FACIT Fatigue Scale.
- Being tested
- Personalized treatment according to molecular diagnosis with HER2DX, Treatment by physician´s choice, blinded to the diagnostic HER2DX test results
- Medical subject headings
- Breast Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Personalized treatment according to molecular diagnosis with HER2DXDevice
Patients with HER2DX high-risk disease:
- Neoadjuvant treatment:
- High HER2DX pCR score: paclitaxel per 12 weeks + trastuzumab +/- pertuzumab per 4-5 cycles.
- Medium HER2DX pCR score: carboplatin + paclitaxel per 12-18 (or docetaxel per 4-6 cycles) + trastuzumab +/- pertuzumab per 4-7 cycles.
- Low HER2DX pCR score: standard of care neoadjuvant CT regimens and HER2 blockade at the investigator's choice.
- Adjuvant treatment:
- pCR at surgery; Trastuzumab +/- pertuzumab up to a total of 18 cycles (including neoadjuvant and adjuvant therapy).
- No pCR at surgery: T-DM1 per 14 cycles.
Patients with HER2DX low-risk disease:
- Neoadjuvant treatment: paclitaxel per 12 weeks + trastuzumab +/- pertuzumab per 4-5 cycles.
- Adjuvant treatment will be according to the pCR status at surgery:
- pCR at surgery: trastuzumab or no adjuvant treatment.
- No pCR at surgery: trastuzumab or T-DM1.
Treatment by physician´s choice, blinded to the diagnostic HER2DX test resultsOther
Patients randomized in ARM A will be treated with standard of care neoadjuvant CT regimens and HER2 blockade at the investigator's choice validated by national and/or international guidelines.
| Study group | Role | What they receive |
|---|---|---|
| Arm A: Treatment by physician´s choice without the diagnostic test results | Other | Treatment by physician´s choice, blinded to the diagnostic HER2DX test results Receives: Other: Treatment by physician´s choice, blinded to the diagnostic HER2DX test results |
| Arm B: Personalized treatment according to molecular diagnosis with HER2DX | Experimental | Personalized treatment according to molecular diagnosis with non-blinded HER2DX results Receives: Device: Personalized treatment according to molecular diagnosis with HER2DX |
What is being measured
The primary outcome is the main question the study is designed to answer.
Global health status (GHS) scale from the EORTC QLQ-C30 questionnaire
The GHS scale is based on two 7-point questions (from very poor to excellent, items 29-30 from EORTC QLQ-C30 questionnaire).
Following EORTC scoring manuals, a linear transformation will be used to standardize the GHS scale to a 0-100 scale.
Measured: Up to 5 years
Score from the FACIT Fatigue Scale
The FACIT Fatigue Scale, version 4 will be used to evaluate PRO measures of quality-of-life concerns related to fatigue.
The FACIT Fatigue Scale is a 13-item questionnaire designed to measure fatigue and its impact on daily life in individuals with various health conditions. Respondents rate their fatigue experiences over the past week on a scale from 0 to 4, with higher scores indicating less fatigue. The total score ranges from 0 to 52.
Measured: Up to 5 years
Secondary outcomes (12)
Functional and symptom scales from the EORTC QLQ-C30 questionnaire.
Change from baseline in all other functional and symptom scales (items 1 to 28) from the EORTC QLQ-C30 questionnaire version 3.0 to assesses cancer-related symptoms, impacts, and treatment-related symptoms.
The items are rated on a 4-point rating scale ranging from 0 ("not at all") to 4 ("very much").
Measured: Up to 5 years
Score of the EuroQol-5D
Change from baseline in the score of the EuroQol-5D.
The 5-level version EQ-5D-5L is a 6-item generic patient-reported preference-based instrument designed to assess health status of patients. The EQ-5D-5L consists of 2 sections:
- the EQ-5D descriptive system comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels of severity: the dimensions of mobility, self-care, and usual activity are rated ranging from 1 (no problem completing task) to 5 (unable to complete task) while the dimensions of pain/discomfort and anxiety/depression are rated ranging 1 (no symptom) to 5 (extreme symptom).
- the EuroQoL visual analogue scale (EQ-VAS) is for patients to self-rate their (global) health state utilizing a vertically oriented visual analogue scale where 100 represents the "best possible health state" and 0 represents the "worst possible health state".
Measured: Up to 5 years
pCR rates
pCR rates between groups at randomization and according to the predefined HER2DX pCR score as a continuous variable and as group categories.
pCR will be defined as the complete absence of invasive carcinoma in the breast and axillary lymph nodes on histological examination at the time of definitive surgery, irrespective of in situ carcinoma in the breast.
Measured: Up to 5 years
Residual cancer burden (RCB)
RCB between groups at randomization and according to HER2DX pCR score as a continuous variable and as group categories.
Residual cancer burden (RCB) is defined as classes 0, 1, 2 and 3, according to the MD Anderson Cancer Center recommendations by local evaluation.
Measured: Up to 5 years
Invasive disease-free survival (iDFS)
Invasive disease-free survival (iDFS) between groups at randomization and according to HER2DX pCR score in continuous variable and risk group.
iDFS is defined as the time from surgery until the date of the first occurrence of one of the following events: recurrence of ipsilateral invasive breast tumor, recurrence of ipsilateral locoregional invasive disease, a distant disease recurrence, contralateral invasive breast cancer, second primary or death from any cause.
Measured: Up to 5 years
Distant metastasis free survival (DMFS)
Distant metastasis free survival (DMFS) between groups at randomization and according to HER2DX pCR score in continuous variable and risk group.
DMFS is defined as the time from surgery to date of first event of distant metastatic recurrence or death (any cause). Contralateral breast cancer and secondary cancers will not be considered. Patients who do not have a DMFS event will be censored at the last recurrence assessment. Patients alive with no evidence of metastasis at the time of their last visit are censored at the time of the last examination.
Measured: Up to 5 years
Recurrence-free interval (RFI)
Recurrence-free interval (RFI) between groups at randomization and according to HER2DX pCR score in continuous variable and risk group.
RFI is defined as from surgery until the date of the first occurrence of one of the following events: recurrence of ipsilateral breast tumor (in situ or invasive), recurrence of ipsilateral locoregional invasive disease, a distant disease recurrence, contralateral invasive breast cancer or death from breast cancer.
Measured: Up to 5 years
Event free survival (EFS)
Event free survival (EFS) between groups at randomization and according to HER2DX pCR score in continuous variable and risk group.
EFS is defined as the time from randomization to the first documented disease recurrence, unequivocal tumor progression determined by the treating investigator, or death from any cause, whichever occurs first.
Measured: Up to 5 years
Incidence, duration, and severity of adverse events (safety and tolerability)
Incidence, duration, and severity of adverse events (AEs) assessed by the NCI Common Terminology for Classification of AEs (CTCAE) version 5, including dose reductions, delays, and treatment discontinuations.
Measured: Up to 5 years
CAHPS cancer care survey (AHQR)
Patient-reported Experience Measurement (PREM) data will be elicited from the patients in this study to fully understand the experience of patient.
Team accessibility, Communication, Information from care providers, Care continuum coordination, respect and courtesy, secondary effects management, shared-decision making, language barriers and overall care perception, will be evaluated using the Drug Therapy Team survey and the Supplementary Items survey from the CAHPS cancer care survey (AHQR).
The Drug Therapy Team Survey is a 56 items questionnaire designed to measure accessibility to the care team, quality of information provided, quality of the visit, management of the impact of the disease on daily life, quality of the administration staff support, and a global scale from 0 to 10 to rate the quality of the team.
The supplementary items survey is a 16 items questionnaire and measure three dimensions of experience: access, information and shared-decision making.
Measured: Up to 5 years
Economic impact of the HER2DX test
Health economic evaluation to analyse the cost-effectiveness in patients with and without HER2DX test information, not only direct cost for hospitals/public health system, but also indirect cost from a societal perspective.
The EuroQol-5D-5L questionnaire will be used to calculate a health status utility score for use in health economic analyses.
Measured: Up to 5 years
Work productivity
To evaluate whether the potential treatment de-escalation following tailored treatment by HER2DX could have impact in the work productivity using the Work Productivity and Activity Impairment Questionnaire (WPAI- GH).The WPAI-GH is a 6-item instrument that gauges absenteeism (missed work time due to the health issue), presenteeism (decreased productivity while working due to the health problem), overall work hindrance, and limitations in daily activities.
Measured: Up to 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Jun 2024
- Study start11 Oct 2024
- Primary completionNov 2028 (estimated)
- Study completionNov 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HER2-positive Breast CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 304 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Fundacio Clinic Barcelona
- Sponsor type
- University, hospital or other
- Collaborators
- SOLTI Breast Cancer Research Group, Austrian Breast & Colorectal Cancer Study Group, UNICANCER, Westdeutsche Studiengruppe GmbH (WSG), Istituto Oncologico Veneto IRCCS, University College Cork, University of Padova, Istituto Europeo di Oncologia, National University of Ireland, Galway, Ireland, The Sheba Fund for Health Services and Research, Erasmus University Rotterdam, Medical University of Vienna, Institut Català d'Oncologia, Europa Donna, Reveal Genomics
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06446882
- Sponsor's protocol ID
- HCB-ONC002
- Acronym
- DEFINITIVE
- Status last verified
- Feb 2026
- First submitted
- 27 May 2024
- Last updated
- 20 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No